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Diabetes mellitus is a group of disorders characterized by prolonged high levels of circulating blood 
glucose. Type 1 diabetes is caused by decreased insulin production in the pancreas whereas type 2 
diabetes may develop due to obesity and lack of exercise; it begins with insulin resistance whereby cells 
fail to respond properly to insulin and it may also progress to decreased insulin levels. The brain is an 
important target for insulin, and there is great interest in understanding how diabetes affects the brain. 
In addition to the direct effects of insulin on the brain, diabetes may also impact the brain through 
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modulation of the inflammatory system. Here we investigate how perturbation of circulating insulin 
levels affects the expression of Hes3, a transcription factor expressed in neural stem and progenitor cells 
that is involved in tissue regeneration. Our data show that streptozotocin-induced β-cell damage, high 
fat diet, as well as metformin, a common type 2 diabetes medication, regulate Hes3 levels in the brain. 
This work suggests that Hes3 is a valuable biomarker helping to monitor the state of endogenous neural 
stem and progenitor cells in the context of diabetes mellitus.
There is concern that diabetes and, more generally, aberrant insulin regulation, have a negative impact on brain 
function1. In fact, even common medication for diabetes such as metformin may impact the brain in ways that 
are not yet well understood as metformin has been shown to alter the self-renewal and differentiation prop-
erties of neural stem cells in vitro and in vivo2,3. It is, therefore, important to identify molecular mechanisms 
by which diabetes mellitus may affect the brain, either directly via alterations in the levels of circulating glu-
cose and insulin or indirectly through effects on the immune/inflammatory system. Here we investigated how 
streptozotocin-induced β-cell damage, high fat diet, and metformin administration regulate the expression of 
Hairy and Enhancer of Split 3 (Hes3) in the adult mouse brain.
We focused on Hes3 because (a) we previously showed that it is involved in various paradigms of brain dam-
age and regeneration4–7, (b) it is also expressed in neural stem cells4, and (c) Hes3 is regulated by insulin4–6. 
Hes3 belongs to the Hes superfamily of basic helix-loop-helix (bHLH) transcription factors that include the Hes 
and Hey (Hes-related with YRPW motif) members8–10. Hes1 and Hes5 are direct targets of Notch signaling and 
their expression is often used as an indicator of canonical Notch signaling activity10. In contrast, Hes3 is an indi-
rect target of Notch signaling; following Notch receptor activation, a pathway involving phosphatidylinositol-4, 
5-bisphosphate 3 (PI3) kinase, Protein kinase B (Akt), mechanistic target of rapamycin (mTOR), and Signal trans-
ducer and activator of transcription 3 - Serine (STAT3-Ser) phosphorylation leads to Hes3 expression, which can 
be used as an indicator of the activity of this non-canonical Notch signaling branch4.
Hes3 is of interest because emerging data shows that it is an important regulator of regeneration in both the 
pancreas and brain. In cultured mouse insulinoma cells (MIN6), Hes3 knockdown and overexpression studies 
revealed that Hes3 regulates the expression of pancreatic and duodenal homeobox 1 (Pdx1), an important gene 
in pancreatic islet health and insulin production; it also regulates the expression of insulin itself11. Hes3 null mice 
are more sensitive to pancreatic islet damage by the toxin streptozotocin (STZ; used to model type 1 diabetes), 
compared to wild type (WT) mice, and regenerate beta cell mass less efficiently11,12. In the brain, Hes3 is expressed 
in putative neural stem cells (NSCs) and progenitor cells4,6. Cultured NSCs also express Hes3; expression is lost 
following their differentiation13–15. Various pharmacological treatments that induce Hes3 expression promote cell 
survival in culture and the number of Hes3-expressing cells in vivo4–6,13–17. This is followed by powerful neuropro-
tection and disease modification in models of ischemic stroke and Parkinson’s disease4–6. Hes3 null mice exhibit 
lower levels of myelin basic protein (MBP) in the brain, indicating insufficient numbers of oligodendrocytes or 
reduced myelination7. In summary, Hes3 plays important roles in various tissues and organs, including the brain, 
where it protects them from damage and enables them to regenerate efficiently.
In this work we demonstrate, for the first time, that the expression of Hes3 in the brain is regulated in mice 
subjected to streptozotocin-induced β-cell damage, high fat diet, and metformin administration. We establish 
Hes3 as a biomarker to monitor the brain in animal models that are widely used to study various aspects of dia-
betes mellitus. Future studies will address whether Hes3 is also regulated in diabetes patients, which parameters 
of insulin deregulation and/or diabetes mellitus are primarily responsible for Hes3 regulation, and the roles that 
Hes3 plays in the progression of diabetes-related phenotypes.
Results
Streptozotocin-induced β–cell damage and high fat diet regulate Hes3 expression in the brain. 
As described in the introduction, we hypothesized that brain Hes3 expression would be altered in mouse models 
of diabetes, in which insulin signaling is perturbed. Such a result would provide novel information, at the molec-
ular level, of how such perturbations might be affecting the brain. We used streptozotocin (STZ) to induce insulin 
deficiency. STZ-induced β–cell damage is an established model to study type 1 diabetes in rodents. High dose STZ 
induces hyperglycemia and leads to insulin deficiency resulting from selective β-cell damage in the pancreas18,19. 
Furthermore, we studied mice fed a high-fat diet (HFD) as there is a general agreement that feeding a high calorie 
diet results in impaired glucose homeostasis and at least a pre-diabetic state comprising hyperglycemia, hyperin-
sulinemia and insulin resistance20.
To measure Hes3 expression, we prepared mRNA extracts from mouse brains where the olfactory bulb and 
all parts caudal to the cortex were removed. Mice were carefully age-matched because, as we observed using PCR 
analysis, expression of Hes3 (both isoforms: Hes3a and Hes3b) drops with age (Fig. S1a). A polyclonal antibody 
against Hes3 further confirmed the reduction in Hes3 expression with age (Fig. S1b,c). The data are consistent 
with a role of Hes3 in the NSC/progenitor cell population.
In the pancreas, the toxin streptozotocin (STZ) induces a powerful increase in Hes3 expression, possibly in an 
effort to promote regeneration of pancreatic islet cells11,12,21. Here we addressed whether similar effects can also 
be observed in the brain. STZ is used to damage pancreatic islet cells and produce animal models for the study of 
type 1 diabetes that exhibit reduced production and systemic circulation of insulin18,19,22. Consistent with pub-
lished studies, mice treated with STZ exhibited increased glucose levels and reduced insulin levels (Fig. S1d,e). In 
these mice, Hes3a and Hes3b mRNA levels in the brain were significantly increased; in contrast, the mRNA levels 
of the canonical Notch signaling targets Hes1 and Hes5 were not significantly altered (Fig. 1a). These data show 
that intraperitoneal administration of STZ leads to Hes3 expression changes in the brain.
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HFD in mice leads to a complex condition that involves elevated circulating insulin (an activator of Hes3) as 
well as complex inflammatory responses (some of which promote and others that are predicted to oppose Hes3 
expression)11,15. It is therefore difficult to predict the effect of particular HFD paradigms on brain Hes3; here we 
investigated this question using established HFD protocols. In both the short and long HFD feeding groups the 
mice gained BW and exhibited increased insulin and glucose levels (Fig. S1f–h). In the short HFD feeding group, 
Hes3a, Hes3b, Hes1, but not Hes5 expression were reduced, relative to the short normal diet (ND) feeding group; 
in the long HFD feeding group, Hes3a and Hes3b expression showed a tendency to decrease, compared to the 
long ND feeding group, but did not reach statistical significance. Again, Hes1 but not Hes5 levels also dropped 
(Fig. 1b,c). We used a separate group of mice, fed a HFD for an intermediate period (16 weeks), to identify par-
ticular brain areas where Hes3 mRNA levels are regulated. With this group, we dissected distinct brain areas: 
Hypothalamus (HPT), Cerebellum (CBL), and the Remaining Brain without HPT, CBL, and olfactory bulbs that 
we denote here as “RB”. HPT is involved in metabolic regulation and it expresses Hes323. Hes3 is highly expressed 
in the CBL although its roles are unknown; RB would provide an overview of Hes3 regulation in the remaining 
brain areas. In this group of mice we measured significant reductions in both Hes3a and Hes3b levels in RB, HPT, 
and CBL (Significant changes: RB: Hes3a and Hes3b; HPT: Hes3a; CBL: Hes3a and Hes3b) (Fig. 1d). These results 
show that streptozotocin-induced β-cell damage and HFD induce significant alterations in the expression of Hes3 
in the brain.
Figure 1. Streptozotocin-induced β–cell damage and high fat diet regulate Hes3 expression in the brain. (a) 
STZ regulates Hes3a and Hes3b levels (N = 6–7). (b,c) HFD (short and long feeding) regulates Hes/Hey gene 
expression (N = 4–7). (d) HFD (16 weeks) regulates Hes3 expression in different brain areas. The heatmap 
shows average gene expression for Hes3a and Hes3b in different brain areas (BR, HPT, CBL; N = 5–8). [Data are 
means ± SEM. Mann-Whitney test; *p < 0.05. HPRT was used as a reference gene]. See also Fig. S1.
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Metformin regulates Hes3 expression in vivo and in vitro. We hypothesized that metformin admin-
istration would alter brain Hes3 expression. To show this could have important clinical connotations as many 
patients are prescribed metformin. Metformin is a widely prescribed medication for type 2 and some cases of 
type 1 diabetes mellitus that opposes hyperglycemia and improves insulin sensitivity24,25. It regulates a variety 
of signaling pathways, suggesting that it may have additional effects. Indeed, metformin also appears to have 
anti-inflammatory effects irrespective of diabetes mellitus status26,27, anti-tumor effects28,29, as well as several 
effects in the living brain including the promotion of neurogenesis and improved spatial memory formation30,31. 
Because it regulates signaling pathways that intercept with Hes3, such as mTOR4,32,33, we addressed the effect of 
metformin on Hes3 expression in the living brain.
We isolated RNA from RB, HPT, and CBL as described above. Metformin affected the expression of multiple 
Hes/Hey genes in the living brain (Significant changes: RB: Hes6, Hey1, Hey2, HeyL; HPT: Hes3b, Hes5, Hey2, 
HeyL; CBL: No significant changes) (Figs 2a; S2a–d). Metformin did not significantly affect BW; fasting glucose 
levels were slightly but significantly reduced; fasting insulin levels were slightly but not significantly increased 
(Fig. S2e–h). Overall, metformin reduced Hes3 expression in the hypothalamus of the adult mouse brain.
To address whether metformin acts directly on NSCs, we used established culture systems of primary mouse 
fetal NSCs (fNSCs). Dose response experiments demonstrated that 500 µM metformin reduced cell number and 
5-ethynyl-2′-deoxyuridine (EdU) incorporation; cell morphology changed to a more differentiated appearance 
with longer processes (Figs 2b–d; S2i). Together, these results suggest that metformin opposes self-renewal and 
promotes cell differentiation. Time course experiments revealed a time-dependent increase in Hes3a and Hes3b 
mRNA levels; at 72 hours we observed increased mRNA levels of Hes3a and Hes3b but not Hes1 or Hes5 (Fig. 2e,f).
These data show that metformin increases Hes3 levels in cultured NSCs, although it decreases Hes3 expression 
in vivo. We speculate that the expression increase in vitro may be a response to the stress caused to the cells by 
metformin or due to changes induced by the onset of the differentiation process. In support of this, we show a 
transient increase in immunoreactivity for Hes3 when cultured NSCs start expressing markers of neurons (TUJ1) 
and oligodendrocytes (CNPase) (Fig. S2j). Overall, our data show effects of metformin on Hes3 expression in 
NSCs isolated from the fetal mouse brain. Future experiments may address whether the changes in Hes3 expres-
sion mediate effects of metformin to brain function.
Exendin-4 (Ex-4) is another commonly used type-2 diabetes medication. We previously showed that it 
induces Hes3 expression in a cultured mouse insulinoma cell line11. Unlike metformin, Ex-4 promoted cultured 
NSC growth at concentrations (200 nM) that induced Hes3 expression (Fig. S3a,b). Also unlike metformin, Ex-4 
did not reduce EdU incorporation (Fig. S3c,d). qPCR analysis showed that Ex-4 significantly increased Hes3a 
and Hes3b mRNA levels, in a time-dependent manner (Fig. S3e). At 72 h of treatment (the time point when Hes3 
expression induction reached significance), we did not observe a significant change in Hes1 expression; however, 
we did measure a significant induction of Hes5 expression (Fig. S3f). These results dissociate the increase in Hes3 
expression from cell growth and are consistent with the hypothesis that the increase in Hes3 expression by met-
formin may be part of a stress response to the treatment.
Hes3 null mice exhibit a quasi-normal phenotype. We established Hes3 expression as an indicator 
that streptozotocin-induced β-cell damage, high fat diet, and metformin administration affect the brain. It is not 
yet clear what consequences these changes may have in the health of the experimental models, despite the fact 
that we previously showed, using Hes3 null mice, that the complete lack of Hes3 leads to increased sensitivity and 
impaired regeneration in the pancreas11,12 (using the STZ model) and in the brain7 (following cuprizone-induced 
damage to oligodendrocytes). Extensive future work with conditional genetic mouse models may address 
the roles of Hes3 in different tissues and organs, in the progression of diabetic and brain-related phenotypes. 
However, in order to obtain first-level information on possible Hes3 roles, we performed an extensive phenotypic 
analysis of the Hes3 null (“knockout”) mouse strain.
Homozygous Hes3 null mice are generally healthy and breed normally9 but also have phenotypes that become 
obvious under stress5,7,11,12. We performed particular phenotypic analyses of the Hes3 null mice following either a 
ND or a HFD. A summary of the results is presented in Table 1. The full report is provided at https://www.mouse-
clinic.de (Click on “phenomap” and search for project “Hes3_KO”).
First, we investigated whether the expression of other members of the Hes/Hey gene family is altered in the 
brains of the Hes3 null mice. We expected this because members of this family are known to suppress the expres-
sion of other members10. Because Hes1 and Hes5 are established mediators of canonical Notch signaling, such a 
result would demonstrate that key pathways in neural stem cell biology are also affected.
We found that in ND, male Hes3 null mice showed significant alterations in the expression of other Hes/
Hey gene family members in the brain, compared to WT; these alterations were much less pronounced in HFD 
(Figs 3a; S4a–g). These results show that the lack of Hes3 alters the equilibrium of the other Hes/Hey genes and 
that this outcome is affected by diet.
We continued our investigation of the consequences of lack of Hes3 by focusing on the expression of 
Microphage Migration Inhibitory Factor (MIF). Low-grade inflammation is a hallmark of type 2 diabetes melli-
tus. Of the inflammatory cytokines, MIF has been demonstrated to positively regulate Hes3 expression in isolated 
NSC cultures15. We addressed how MIF levels are altered by diet and by the lack of Hes3 (comparing WT and 
Hes3 null mice).
We compared MIF mRNA levels in RB and HPT of WT and Hes3 null mice in both ND and HFD (Fig. 3b,c). 
In ND we observed the following: Hes3 null mice express a lower amount of MIF in the RB compared to WT. 
In HPT, the difference did not reach statistical significance. In HFD we observed the following: MIF expression 
showed no significant difference between WT and Hes3 null mice in the RB, whereas in the HPT there was a 
non-statistically significant trend towards an increase. MIF expression level in WT mice was affected by diet; 
HFD reduced MIF expression in the RB. In contrast, we observed an increase in the HPT.
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Whereas MIF levels were altered by diet in WT mice in both the RB and HPT, Hes3 null mice did not exhibit 
changes in MIF expression in the RB due to diet. They did, however, exhibit an increase in HPT, similarly to WT 
mice. The results suggest a complex interplay among Hes3, diet, and MIF in different brain areas and call for addi-
tional studies to address the potential reciprocal regulation between Hes3 and the inflammatory system.
Figure 2. Metformin regulates Hes3 expression in vivo and in vitro. (a) Metformin in drinking water for 2 
months regulates Hes/Hey gene mRNA levels in the brain (N = 5–12; CTRL: Control; MET: Metformin). 
The heatmap shows average gene expression levels in different areas of the brain. (b) Metformin reduces cell 
number (DAPI-stained nuclei counts) in a dose-dependent manner (N = 4; 72 h, 500 µM). (c) Metformin 
(500 µM) reduces EdU incorporation in vitro (N = 3; 72 h; 1-tailed t-test). (d) Brightfield images of control and 
metformin-treated (500 µM, 72 hours) primary fNSC cultures. [Scale bar: 30 μm]. (e,f) Metformin (500 µM) 
regulates Hes3a and Hes3b mRNA levels in vitro (N = 3, 72 h). [Data are means ± SEM. Mann-Whitney 
test unless noted otherwise; *p < 0.05. HPRT was used as a reference gene; for the in vitro experiments, data 
were collected from at least 3 separate experiments]. See also Fig. S2.
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The expression changes in the brain prompted us to investigate potential phenotypes that relate to brain 
function. We performed a set of neurological phenotypic analyses in Hes3 null and WT mice fed a ND. We did 
not observe significant differences between the Hes3 null and WT mice in terms of behavior (open field test), 
neurology (Modified SHIRPA, auditory brain stem response, rotarod test, grip strength), nociception (hot plate 
test), and eye functions (Scheimpflug imaging, OCT, LIB, drum). Regarding energy metabolism, indirect cal-
orimetry showed no differences in ND, whereas NMR showed a trend towards increased fat content over time 
mainly in male mutants. We also found no dysmorphology phenotypes (Anatomical observation, X-ray, MicroCT 
scans of dissected bones), in ND. We also did not find any clear cardiovascular phenotypes in ND; awake ECG 
Echocardiography in ND showed a very mild increase in septum width in systole (males), a very mild reduction 
in heart rate and very mild alterations in QRS, ST and Qtdisp intervals (probably by chance) (Table 1; https://
www.mouseclinic.de; Fig. S5a-l, and Supplementary Material-GMC Report).
The very mild phenotypes relating to behavior, neurology, and nociception pushed our focus to other poten-
tial phenotypes, for example, those that are relevant to metabolism. Using male mice, we found that in ND, Hes3 
null mice behaved similarly to wild-type (WT) mice in terms of BW gain; in HFD, Hes3 null mice gained less 
BW, compared to WT mice (Fig. 3d). In both ND and HFD, Hes3 null mice showed lower glucose levels during 
the course of the ipGTT compared to WT mice, resulting in slightly lower AUC values especially for the second 
part of the test [AUC (30–120 mins)], which might indicate an improved glucose tolerance (HFD: Fig. 3e; ND: 
Screen Method Phenotype summary Hes 3 null
NORMAL DIET
Energy Metabolism Indirect calorimetryNMR
-None
- Trend towards increased fat content over time mainly in male 
mutants
Behavior
Open field -None
Acoustic startle response, PPI -None
Neurology
Modified SHIRPA,
Auditory brain stem response
Rotarod
Grip strength
-None
-None
-None
-Small trend towards increased fore paw force
Nociception Hot plate -  Shorter reaction time for the first pain reaction in females, trend towards hyperalgesia
Dysmorphology Anatomical observation, X-ray,MicroCT scans (dissected bones) -None
Cardiovascular Awake ECGEchocardiography
-No clear phenotype
-Very mild increase in septum width in systole (males).
-Very mild reduction in heart rate and thus RR interval prolongation
- Very mild alterations in QRS, ST and Qtdisp intervals (probably by 
chance)
Eye Scheimpflug imaging, OCT, LIB, drum -Slight decrease in retinal thickness (females)
Clinical Chemistry
IpGTT
Insulin levels
Clinical chemical analysis
Hematology
- IPGTT: Mild trend downwards in males and upwards in females for 
AUC values.
-None
- Trend towards changes in creatinine and fructosamine (mainly 
females) concentrations
-Hematology: Slightly lower platelet distribution width
Immunology Flow cytometry analysis of Peripheral Blood Leukocytes
- Subtle alterations in the leukocyte subpopulations, however no 
evidence for pathological effects in the immune system:
-increased frequency of B cells
-decreased frequency of CD4 single positive T cells
-increased frequency of CD4 CD8 double positive T cells
-increased proportion of CD8 single positive T cells (females)
-increased CD44 expression on CD4+ T cells
Allergy ELISA (IgE concentration)TEWL
-None
-None
Pathology Macro & microscopic analysis -None
HIGH FAT DIET
Energy Metabolism
Indirect calorimetry, NMR -None
Body temperature -Slight increase in males and females
Fat mass -Mild decrease in females
Allergy
TEWL -Slight increase in females
Body surface temperature -None
Clinical Chemistry IpGTT -IPGTT: Mild trend downwards in males for AUC values.
Table 1. Summary of phenotypic analysis. WT and Hes3 null mice were subjected to a number of 
phenotypic assays, as summarized in the table. A full report of the analyses is presented in the Supplementary 
Material section. [NMR: Nuclear magnetic Resonance; PPI: Prepulse Inhibition; SHIRPA: http://www.
har.mrc.ac.uk/services/phenotyping/neurology/shirpa.html; MicroCT: Micro Computer Tomography; 
ECG: electrocardiography; OCT: Optical Coherence Tomography; LIB: laser interference biometry; 
ipGTT: intraperitoneal glucose tolerance test; PBCs: Peripheral Blood Leukocytes; ELISA: enzyme-linked 
immunosorbent assay; TEWL: Transepidermal water loss; AUC: Area Under Curve].
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Supplementary Material-GMC Report). Male Hes3 null mice fed a HFD also exhibited a trend (p = 0.053) towards 
higher rectal and body surface temperature (Fig. 3f). [Two Way ANOVA analysis revealed a significant increase in 
the body temperature of WT versus KO mice when both male and female mice were analyzed together (p = 0.036; 
N = 14,14)] (Supplementary Material-GMC Report).
Beyond the brain, Hes3 null mice in ND also exhibited subtle alterations in the leukocyte subpopulations 
[increased frequency of B cells, decreased frequency of CD4 single positive T cells, increased frequency of CD4 
Figure 3. Hes3 null mice exhibit a quasi-normal phenotype. (a) Heatmap of the average qPCR gene expression 
levels of different Hes/Hey genes in WT and Hes3 null mice in the brain areas indicated under ND and under 
HFD conditions (for 16 weeks; N = 4–8). (b) MIF expression in RB of WT and Hes3 null mice under ND and 
HFD (qPCR; N = 3–6). (c) MIF expression in HPT of WT and Hes3 null mice under ND and HFD (qPCR; 
N = 4–7). (d) BW progression in mice fed a ND (for 16 weeks; N = 5, 5, same cohort as in (a)) or a HFD (for 
16 weeks; N = 11, 9). (e) Hes3 null mice exhibit lower scores (and AUC values) in the ipGTT assay in HFD 
(after 24 weeks of HFD; see https://www.mouseclinic.de) (N = 11,9). (f) Hes3 null mice exhibit a trend towards 
higher rectal and body surface temperature than controls [Same cohort of mice as in (e); N = 7,7]. [Data are 
means ± SEM. Mann-Whitney test; *p < 0.05. HPRT was used as a reference gene]. See also Fig. S4.
www.nature.com/scientificreports/
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CD8 double positive T cells, increased proportion of CD8 single positive T cells (females), and increased CD44 
expression on CD4+ T cells], although no evidence for pathological effects in the immune system was observed 
(Table 1 and Supplementary Material-GMC Report).
Overall, the phenotypic analyses of the Hes3 null mouse strain show mild phenotypes along with an altered 
equilibrium of the expression of multiple other Hes/Hey genes in the brain and point towards multiple roles that 
may be addressed in future studies.
Discussion
Diabetes affects the brain in ways that are insufficiently understood34. Ironically, diabetes medication such as 
metformin also affects the brain, and we don’t know the consequences to the patient. It is important to reveal the 
molecular mechanisms that are affected in order to be able to predict outcome and design appropriate therapeutic 
interventions. A sensitive biomarker in the brain whose expression levels change in response to disease progres-
sion and metformin administration would be a valuable new tool. Such a biomarker would be even more valuable 
if it is already known to play roles in brain regeneration.
Here we used a mouse model of type 1 diabetes mellitus (the streptozotocin-induced β-cell damage model), a 
mouse model of high fat diet exhibiting systemic inflammation and insulin resistance, often used to study aspects 
of type 2 diabetes, and a mouse model of metformin administration to establish the transcription factor Hes3 as 
such a biomarker. We show that the expression of Hes3 in the brain is regulated in all three mouse models. We 
present a conceptual diagram of how Hes3 may be regulated by a number of parameters, including signal trans-
duction pathways, inflammatory responses, insulin levels, age, etc. (Fig. S6).
Future work may address the mechanisms by which Hes3 is regulated in the animal models we employed, as 
well as, potentially in patients with type 1 and type 2 diabetes, and during metformin administration. It may also 
address the impact that Hes3 expression changes might have to the brain. For now, we may speculate on a number 
of possibilities.
First, insulin may directly regulate Hes3+ cells in the brain. Type 1 and type 2 diabetes mellitus as well as being 
overweight or obese are known risk factors for developing cognitive impairment and dementia35–40. In part, this 
risk is thought to be due to aberrant insulin actions directly to the brain. Beyond stimulating glucose metabo-
lism, insulin (along with the related hormone Insulin-like growth factor 1, IGF-1) has multiple functions in the 
brain, supporting the survival of neurons and oligodendrocytes41, promoting synaptic integrity and plasticity42, 
and helping working memory and cognition43. At the signal transduction level, post-mortem analysis of brains 
from patients with Alzheimer’s disease reveals perturbed signaling downstream of the insulin receptor, including 
reduced insulin and IGF-1 binding to their receptors and impaired PI3K/Akt signaling44–47. Hes3 is regulated by 
insulin, as we previously showed in neural stem cell cultures as well as in vivo4–6. In fact, Hes3 is a key component 
of a signal transduction pathway that is involved in a variety of regeneration paradigms in different cell types in 
vitro and in different tissues in vivo4–6,11,12,14,15,21,48–50. It is possible, therefore, that altering circulating insulin levels 
may lead to sufficient changes in brain interstitial fluid levels, and that may directly affect Hes3-expressing cells. 
But it has proven complicated to determine how insulin levels in the interstitial fluid of the brain change when cir-
culating insulin levels are altered51–53. Cerebrospinal fluid (CSF) levels have been used as surrogate measurements 
for brain interstitial levels. However, this may not be an accurate measurement as insulin is thought to predomi-
nantly enter the brain via the blood-brain barrier, as has been expertly reviewed previously54. In addition, elevated 
extracellular glucose concentrations have been suggested to be able to induce insulin production from cerebral 
cortical neuroglial cells52–55; how that may contribute to local Hes3 expression regulation is not yet addressed. 
Alternatively, insulin that reaches the cerebrospinal fluid (CSF) may also be able to induce Hes3 expression in 
certain brain areas adjacent to the ventricles; in support of this, in the original studies demonstrating endogenous 
NSC activation by insulin and other reagents, the treatments were injected into the lateral ventricles of adult 
rats4–6.
Second, oxidative and inflammatory responses may also play an important role in regulating Hes3 expression 
in different cell types56,57. It is important to not group all inflammatory cytokines together when addressing their 
effects on Hes3. Whereas many inflammatory cytokines (e.g., the interleukin family) activate the JAK-STAT sign-
aling pathway and would thus be expected to suppress Hes3 expression, MIF has been shown to promote it via an 
Akt/mTOR/STAT3-Ser mechanism11,12,15,21. Therefore, the precise inflammatory responses activated in different 
disease models (or, at different stages of the same model) may contribute to the exact Hes3 expression patterns 
that we observed. Such a task will require a detailed determination of the production of multiple cytokines at 
different time points, and an assessment of their potential to induce or suppress Hes3 expression. A better under-
standing of the interaction between specific inflammatory responses and Hes3 may help inform drug discovery 
programs aimed at both modulating inflammation and protecting brain tissue. Future studies may also address 
how Hes3 expression is specifically altered by oxidative and inflammatory stress components such as oxygen 
radicals produced by the mitochondria of affected cells and activated, nuclear NF-kB. Cross-talk between NF-kB 
and JAK-STAT signaling as well as between reactive oxygen species and JAK-STAT increases the complexity by 
which Hes3 may be regulated58–60.
In addition to the disease models themselves, we hypothesized that metformin, a common medication for 
type 2 diabetes mellitus61,62 would also affect brain Hes3 levels. Our data show different effects of metformin 
on Hes3 expression in vitro and in vivo, arguing for complex mechanisms by which metformin regulates Hes3 
expression. This could be due to the broad range of signaling pathways affected by metformin that include several 
known modulators of Hes34,63,64. Although the precise molecular mechanisms by which metformin affects cells 
are not fully elucidated, studies from various cell systems have identified a number of signaling pathways that 
are involved. In triple-negative breast cancer cell lines, metformin was shown to oppose both JAK/STAT3-Tyr 
activity and STAT3-Ser phosphorylation65. It is possible that, depending on which of the two branches of STAT3 
is mostly affected, the outcome may either favor or oppose Hes3 expression because Hes3 is positively regulated by 
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inducers of STAT3-Ser phosphorylation and negatively regulated by JAK kinase which leads to STAT3-Tyr phos-
phorylation4. In addition, metformin opposes mTOR activation, via 5′ AMP-activated protein kinase (AMPK) 
stimulation32,33,66–68, a function that should also oppose Hes3 expression (mTOR is a positive regulator of Hes3 
expression4). Metformin also regulates insulin-like growth factor 1 (IGF-1) and p38 mitogen-activated protein 
kinases (p38 MAPK) which are signaling components with prominent roles in the self-renewal of NSCs and the 
regulation of Hes3 expression4,5,64. Inflammatory responses triggered by metformin (as well as by type 2 diabetes 
itself)69–71 further complicate the predictability of its effects on Hes3 expression because different inflammatory 
cytokines may have opposite effects on Hes3 expression (depending on whether they predominantly stimulate 
the JAK-STAT or Akt/mTOR pathways, for example). It will be interesting to determine whether the complex 
mechanisms by which metformin may regulate Hes3 contribute to the lack of consensus regarding the drug’s 
potential role as a therapeutic agent in neurodegenerative disease72,73. It is conceivable that patients on metformin 
will benefit from concomitant treatments that modulate the inflammatory response in the brain such that Hes3 
levels are maintained within an appropriate range. For example, promoting MIF responses while suppressing 
interleukin responses may have beneficial effects on the neural stem/progenitor population, on neurons, and on 
cognitive function.
Our data implicate aging in the regulation of Hes3. This may not be too surprising, given that there is a general 
consensus that neural stem cell biomarkers decrease with age. Our observation that Hes3 expression in the brain 
drops with age might have important connotations in diabetes mellitus. This is in light of studies suggesting dif-
ferences between children and adults with type 1 diabetes in the way that their brain responds to the disease. In an 
imaging study involving a large cohort of children with type 1 diabetes, it was revealed that hippocampal volumes 
were increased in the children with the largest number of severe hypoglycemic episodes74. This result was inter-
preted as a manifestation of sensitivity of the hippocampus to acute hypoglycemia. It is contrary to data obtained 
from studies with adult type 1 diabetes patients that revealed no changes in hippocampal volume75. Animal stud-
ies reinforce the hypothesis that postnatal age affects the way that the brain responds to hypoglycemia1,76. It will 
be of significant interest to determine the potential role of Hes3 in this age-related effect. It will also be valuable 
to determine whether the abundant, Hes3-expressing endogenous NSC/progenitor cell population in the hip-
pocampus is affected in these children. The postnatal hippocampus is one of the few brain areas where regular 
neurogenesis is observed from a local pool of stem/progenitor cells77. Many putative stem/progenitor cells in the 
hippocampus co-express Hes3 and their number increases in vivo when pharmacological agents that induce Hes3 
expression are injected into the brain17. Therefore, one could expect that the combination of a high-Hes3 young 
brain and elevated Hes3 expression due to diabetes mellitus could impact the stem cell-rich cytoarchitecture of 
the hippocampus. Given that MIF expression drops with age78,79 and is associated with longevity80, it is intriguing 
to speculate that age-dependent MIF expression changes may be, in part, responsible for the accompanying drop 
in Hes3 expression.
The age-based differences in brain Hes3 expression are particularly relevant in light of current efforts to 
assess new clinical potential of metformin. One study (Targeting Aging with Metformin, TAME; https://www.
afar.org/natgeo/) will assess its anti-aging potential81; it may be of interest to obtain more information on how 
Hes3 expression is regulated in humans by age and by metformin itself. The other study (Autoimmune Diabetes 
Accelerator Prevention Trial, adAPT; http://adaptdiabetes.org/) involves administering metformin to healthy 
children who are at risk of developing type 1 diabetes as a prevention strategy; it may be beneficial to assess 
differences in brain Hes3 expression in detail between children and adults in order to potentially better predict 
unforeseen consequences.
Given the potential of Hes3 as a biomarker, it is valuable to obtain information on its potential roles. In our 
past work and here we have focused on measuring Hes3 expression changes in the damaged and regenerating 
pancreas and brain. But it is expressed in various other tissues as well, where its roles are much less known. Here 
we provide a first-order phenotypic analysis of Hes3 null mice. Future studies may involve the use of conditional 
and inducible genetic mouse models so as to obtain phenotypic information on Hes3 in particular time points 
and tissues. For now, the phenotypic analysis we present provides some clues to its roles.
Hes3 null mice exhibit differences in the expression of other Hes/Hey gene family members in the brain, rel-
ative to WT mice. They also show altered MIF expression as well as differences in leukocyte lineage frequencies 
are (albeit mildly), suggesting potential consequences in the levels of inflammatory cytokines and in chronic 
low-grade systemic inflammation, a risk factor in many patients with obesity82.
These differences do not seem to obviously affect brain function as phenotypic analyses on behavior, neu-
rology, nociception, and eye function showed no significant differences between Hes3 null and WT mice. It is 
possible, however, that, in the context of an appropriate challenge to the mouse, phenotypic differences might be 
revealed. This is in accordance with our previous work showing that Hes3 null mice exhibit significantly altered 
responses to cuprizone-induced damage of oligodendrocytes in the brain and altered regeneration of oligoden-
drocytes afterwards7. It is possible that the roles of Hes3 become more evident under conditions of challenge. In 
fact, this is very similar to what we observed in the pancreas, in our previous work: Hes3 null mice behave very 
similarly to WT mice, in terms of pancreatic function under normal conditions but exhibit much greater damage 
and reduced regeneration following streptozotocin-induced pancreas damage11,12. Therefore, future work may 
search for disease paradigms where the lack of Hes3 results in clear brain phenotypes.
We report a number of mild phenotypes, some of which are observed under HFD conditions but not on ND 
conditions. For example, we found no differences in BW between Hes3 null and WT mice when fed a ND, but sig-
nificant differences when placed on a HFD. (In a separate cohort of mice placed under a distinct HFD protocol/
composition, we did not observe statistically significant BW changes: Supplementary Material-GMC Report). 
Future studies may investigate the reasons behind this difference (fat tissue composition, thermoregulation, com-
position of diet, immune/inflammatory reactions, animal housing stresses, etc.).
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Conversely, at the molecular level, we observed much more pronounced effects of the lack of Hes3 in ND, 
compared to in HFD, regarding the expression of other members of the Hes/Hey gene family. It is possible that 
because in HFD Hes3 expression is reduced relative to ND, the effect of lacking Hes3 is not as pronounced. It is 
also possible that HFD regulates other Hes/Hey genes independently from Hes3 in a manner that overrides, in 
part, the genetic lack of Hes3.
Here we show that STZ-induced β-cell damage, high fat diet, and metformin administration in vivo regulate Hes3 
levels in the adult mouse brain. Our data establish Hes3 as a potentially valuable biomarker for the impact of diabetes 
on the plasticity potential of the brain. Because Hes3 is a key component of a signal transduction pathway involved in 
neural stem cell biology and regeneration, it may also provide leads towards new therapeutic opportunities.
Methods
All methods were performed in accordance with the relevant guidelines and regulations.
Animals. 6 week-old C57Bl6/J male mice were obtained from Janvier and they were used in accordance with 
the approved guidelines from the Landesdirektion Sachsen. The Hes3 null mouse line was kindly provided by R. 
Kageyama9. At the GMC mice are housed according to the GMC housing conditions and German laws. All tests per-
formed at the GMC were approved by the responsible authority of the district government of Upper Bavaria, Germany.
Microscopy. Brains were dissected, fixed overnight and cryoprotected in 30% sucrose solution phosphate 
buffered saline at 4 °C until sinking. 16 μm brain tissue sections were prepared in the cryostat and mounted 
on glass slides. Immunofluorescence staining for Hes3 was performed as described previously11. Images were 
acquired with a Zeiss LSM780 system. Image analysis was performed using the Fiji software.
Tissue Collection. Brain tissues were dissected on ice. Depending on the experimental plan brain without 
cerebellum and olfactory bulb (indicated as BRAIN), brain without cerebellum, olfactory bulb and hypothalamus 
(indicated as Remaining Brain ‘’RB”), hypothalamus (HPT) and cerebellum (CBL) were dissected. We removed 
the olfactory bulbs for consistency as, sometimes, they are damaged during dissection. RB was split into two 
hemispheres and one was directly processed for RNA extraction. CBL was also divided in two parts and the same 
procedure was followed. Full HPT was used for the RNA extraction. Total RNA was isolated with the High Pure 
RNA isolation kit (Roche, 11828665001) and 1 μg of total RNA per sample was reverse transcribed using Promega 
M-MLV reverse transcriptase (Promega, M170B).
Real-Time PCR. PCR was performed with DreamTaq Green DNA Polymerase (EP0712, ThermoScientific) 
with addition of betaine (5M, B0300, Sigma, B0300). qPCR experiments were performed with SsoFast EvaGreen 
Supermix (172–5201, Biorad) in a CFX384 Real time PCR Detection System83. Primer sets and reaction protocols 
are in Suppl. Tables 1–3. Relative gene expression was evaluated with the ΔΔCt method upon normalization 
to hypoxanthine-guanine phosphoribosyltransferase (HPRT). Primer sets and reaction protocols (Gene: Seq. 
5′—> 3′ FW/Seq. 5′—> 3′ REV/Method) were:
mHes1: AAGATAGCTCCCGGCATTCCAAGC/AGCGCGGCGGTCATCTGC/PCR, qPCR;
mHes3: AAAGCTGGAGAAGGCCGATA/TCCTTGCCTACGTCTCACCA/PCR;
mHes3a: GTGATCTCCAAGCCTCTGATGGAGAA/CAGCTTTCGTTTCCGTATCTGATGTGA/PCR, 
qPCR;
mHes3b: CCAGCAGCTTCCGAAAGATCTCCA/TCTCCAGCTTTCGTTTCCGTATCTGA/PCR, qPCR;
mHes5: CAACAGCAGCATAGAGCAGC/AGGCTTTGCTGTGTTTCAGG/PCR, qPCR;
mHes6: GGTGCAGGCCAAGCTAGAG/TGAAAGCTGCTACCCTCACG/PCR, qPCR;
mHes7: CCCAAGATGCTGAAGCCGTTGGT/AGCTTCGGGTTCCGGAGGTTCT/PCR, qPCR;
mHey1: AGGCATCATCGAGAAGCGCC/AGCTTAGCAGATCCCTGCTTCTCA/PCR, qPCR;
mHey2: TGAGAAGACTAGTGCCAACAGC/TGGGCATCAAAGTAGCCTTTA/PCR, qPCR;
mHeyL: CAGCCCTTCGCAGATGCAA/CCAATCGTCGCAATTCAGAAAG/PCR, qPCR;
mHPRT: AAGCTTGCTGGTGAAAAGGA/TTGCGCTCATCTTAGGCTTT/PCR, qPCR;
mMIF: TTAGCGGCACGAACGATCC/ACAGCAGCTTACTGTAGTTGC/qPCR.
The PCR protocol steps were (Cycling step: Temp, °C/Time/# of cycles): Initial Denaturation: 95/10 min/1; 
Denaturation: 95/4 min/35; Annealing: 60/30 sec/35; Extension: 72/1 min/35; Final Extension: 72/10 min/1.
The qPCR protocol steps were (Cycling step: Temp, °C/Time/# of cycles): Enzyme activation: 95/1 min/1; 
Denaturation: 95/5 sec/40; Annealing-Extension: 60/15 sec/40; Melt Curve: 65–95 °C in 0.5 °C increments/5 sec 
per step/1
Aging. We examined 17 week old mice (from here on referred to as “Young”) and 34 week old mice (from here 
on referred to as “Old”).
Animal models. Single High Dose STZ .  8 week-old mice were injected intraperitoneally 
[phosphate-buffered saline (PBS) vehicle control or STZ (180 mg/kg, Sigma Aldrich, S0130)] and were eutha-
nized 8 weeks later.
HFD. 8 week old mice were fed Normal Diet (ND, 10% kcal % fat, D12450B, OpenSource Diets – Research 
Diets) or High Fat Diet (HFD, 60% kcal % fat, D12450B, OpenSource Diets – Research Diets) and euthanized 
after ~10 weeks (“Short Feeding”) or ~30 weeks (“Long Feeding”). For the HFD feedings performed at the GMC, 
please refer to the GMC Report in the Supplementary Materials section.
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Metformin administration. Metformin was administered in the drinking water (2 g/l, Sigma, D-150959) of 8 
week old mice for 8 weeks. Water was changed 2 times per week.
Metabolic Analyses. Body weight (BW): We measured the BW of the mice weekly at the same time of day. 
Intraperitoneal Glucose-Tolerance-Test (ipGTT): Mice were used for the glucose tolerance test after a 16–18 
hours-lasting overnight food-withdrawal. In the beginning of the test, the body weight of mice was determined. 
For the determination of the fasting blood glucose level, the tip of the tail was scored using a sterilized scalpel 
blade and a small drop of blood was analyzed with the Accu-Chek Aviva glucose analyzer (Roche/Mannheim). 
Thereafter mice were injected intraperitoneally with 2 g of glucose/kg body weight using a 20% glucose solution, 
a 25-gauge needle and a 1-ml syringe. 15, 30, 60 and 120 minutes after glucose injection, additional blood samples 
(one drop each) were collected and used to determine blood glucose levels as described before. Repeated bleeding 
was induced by removing the clot from the first incision and massaging the tail of the mouse. After the experi-
ment was finished, mice were placed in a cage with plentiful supply of water and food. Fasting BW, Fasting Blood 
Insulin and Fasting Blood Glucose levels: Fasting BW and fasting blood glucose were measured with Accu-Chek 
glucose meter (Roche, Mannheim, Germany) and blood samples were collected for fasting insulin concentration 
determination with an Elisa Kit (Crystal Chem) and according to the manufacturer’s instructions.
NSC cultures. Cell isolation. Fetal NSCs (fNSCs) were dissected and cultured from mouse embryos at 
embryonic day 13.5 (E13.5). Cells were grown in serum-free N2 medium; basic fibroblast growth factor [bFGF 
(233-FB-01M, R&D Systems)] was added to the cells at a concentration of 20 ng/ml daily84.
Treatments. Cells were seeded at 10,000 cells per well in a 12 well plate and treated with different concentra-
tions of metformin (Sigma, D-150959) or exendin-4 [Ex-4 (Biotrend, BP0111)], beginning at 24 h after plat-
ing. Cells were fixed after 72 h with 4% paraformaldehyde (PFA) for 20 minutes and nuclei were stained with 
4′,6-Diamidino-2 Phenylindole (DAPI).
Cell number, Proliferation. Cell proliferation was determined after 72 h by incubating the cells with 10 μM 
5-ethynyl-2′-deoxyuridine (EdU) for 5 h and followed by visualization using the Click-IT EdU Alexa Fluor 594 
Imaging Kit (Invitrogen C10339). Five images (using a 20x objective) from each well were acquired (3 wells per 
plate) with a standard Zeiss structured illumination microscope (Zeiss – Axio Observer Z1, inverted) and cells 
were counted using the Fiji software.
PCR/qPCR. For the time-course experiments cells were seeded at 500,000 cells per T25 flask and treatments (0 
or 500 μM metformin) were initiated 24 h after plating. Cells were collected at 6, 24, 48 and 72 h and processed 
directly for PCR/qPCR experiments. Cell culture medium and treatments were changed daily.
Mouse phenotyping. Comprehensive phenotypical characterization of Hes3 null mice was performed at 
the German Mouse Clinic (GMC), Munich, Germany85. 64 mice (16 males, 16 females, 16 control males and 16 
control females) were used beginning at age 9 weeks. Tests were conducted using the protocols described before86 
and referenced at https://www.mouseclinic.de (Click on “VIEW RESULTS OF MUTANT LINES” or “phenomap” 
and search for project “Hes3_KO”). The methods described in Fig. S5 (for Behavior, neurology, and nociception 
phenotyping) as well as additional analyses can also be found in the Supplementary Material-GMC Report.
An additional cohort (11 males, 11 females, 11 control males and 11 control females) was fed a HFD (E15741-
347 (D12492 mod.) Ssniff Spezialdiäten GmbH, Soest, Germany, containing 60 energy-% from beef tallow). 
Mice were subjected to the following tests beginning at age 12–13 weeks: Body composition analysis (qNMR, 
Minispec LF 50, Bruker, Ettlingen, Germany), 21 hours indirect calorimetry (Phenomaster, TSE Systems Gmbh, 
Bad Homburg, Germany), rectal body temperature, body surface temperature (thermosensor: Almemo ZA 9040, 
data logger: Almemo 2290-8, Ahlborn, Holzkirchen, Germany), and ipGTT after overnight food deprivation.
Heat maps. Heat maps were generated in Morpheus https://software.broadinstitute.org/morpheus/.
Statistical analyses. Data are expressed as means ± SEM. Statistical analyses were performed in Graphpad 
Prism (GraphPad Software, Inc., San Diego, CA). The Student’s t test, a Mann- Whitney U test, or one-way 
ANOVA were used and significance was set at p < 0.05. A detailed account of the statistical methods used in the 
phenotypic analysis of the Hes3 null mice is provided in the GMC Report in the Supplementary Materials section.
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request and in the https://www.mouseclinic.de repository (Click on 
“VIEW RESULTS OF MUTANT LINES” or “phenomap” and search for project “Hes3_KO”).
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